CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers [Gastrointestinal Cancer]
Conclusion
In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Enzinger, Burtness, Niedzwiecki, Ye, Douglas, Ilson, Villaflor, Cohen, Mayer, Venook, Benson, Goldberg Tags: Chemotherapy Gastrointestinal Cancer Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Erbitux | Esophagus Cancer | Gastroenterology | Study | Toxicology